Pauline Wimberger: Influence Statistics

Pauline Wimberger

Pauline Wimberger

National Center for Tumor Diseases (NCT/UCC), Dresden, Germany | for the ATTAIN Investigators | Department of Gynecology and Obstetrics, Technische Universität Dresden, ...

Pauline Wimberger: Expert Impact

Concepts for which Pauline Wimberger has direct influence: Venous thromboembolism , Elective surgery , Patients surgery , Sars cov2 patients , Patients sars cov2 , Sars‐cov‐2 infection , Ovarian cancer .

Pauline Wimberger: KOL impact

Concepts related to the work of other authors for which for which Pauline Wimberger has influence: Ovarian cancer , Elective surgery , Antiplatelet agents , Angiogenesis inhibitors , Venous thromboembolism , Sars‐cov‐2 infection , Pulmonary complications .

KOL Resume for Pauline Wimberger

Year
2022

National Center for Tumor Diseases (NCT/UCC), Dresden, Germany

for the ATTAIN Investigators

2021

National Center for Tumor Diseases (NCT/UCC), Dresden, Germany.

2020

Helmholtz-Zentrum Dresden-Rossendorf (HZDR), Dresden, Germany

Prominent publications by Pauline Wimberger

KOL-Index: 11583 . Peri-operative SARS-CoV-2 infection increases postoperative mortality. The aim of this study was to determine the optimal duration of planned delay before surgery in patients who have had SARS-CoV-2 infection. This international, multicentre, prospective cohort study included patients undergoing elective or emergency surgery during October 2020. Surgical patients with pre-operative ...
Known for Surgery Patients | Sars‐cov‐2 Infection | Child Child | International Prospective
KOL-Index: 9613 . BACKGROUND: Antiangiogenic therapy has known activity in ovarian cancer. The investigator-initiated randomised phase 2 TRIAS trial assessed the multi-kinase inhibitor sorafenib combined with topotecan and continued as maintenance therapy for platinum-resistant or platinum-refractory ovarian cancer. METHODS: We did a multicentre, double-blind, placebo-controlled, randomised, phase 2 trial ...
Known for Ovarian Cancer | Progressionfree Survival | Maintenance Therapy | Topotecan Platinum
KOL-Index: 5083 . SARS-CoV-2 has been associated with an increased rate of venous thromboembolism in critically ill patients. Since surgical patients are already at higher risk of venous thromboembolism than general populations, this study aimed to determine if patients with peri-operative or prior SARS-CoV-2 were at further increased risk of venous thromboembolism. We conducted a planned sub-study and ...
Known for Sars‐cov‐2 Infection | Venous Thromboembolism | Surgery Sars | Risk Postoperative
KOL-Index: 5076 . We aimed to determine the impact of pre-operative isolation on postoperative pulmonary complications after elective surgery during the global SARS-CoV-2 pandemic. We performed an international prospective cohort study including patients undergoing elective surgery in October 2020. Isolation was defined as the period before surgery during which patients did not leave their house or receive ...
Known for Elective Surgery | Pre‐operative Isolation | Sarscov2 Infection | International Prospective
KOL-Index: 3373 . OBJECTIVE: DCVAC/OvCa is an active cellular immunotherapy designed to stimulate an immune response against ovarian cancer. We explored the safety and efficacy of DCVAC/OvCa plus carboplatin and gemcitabine in platinum-sensitive ovarian cancer. METHODS: In this open-label, parallel-group, phase 2 trial (ClinicalTrials.gov number NCT02107950), patients with platinum-sensitive ovarian cancer ...
Known for Ovarian Cancer | Dendritic Cell | Based Immunotherapy | Progressionfree Survival
KOL-Index: 3003 . A European consensus conference on endometrial carcinoma was held in 2014 to produce multidisciplinary evidence-based guidelines on selected questions. Given the large body of literature on the management of endometrial carcinoma published since 2014, the European Society of Gynaecological Oncology (ESGO), the European SocieTy for Radiotherapy & Oncology (ESTRO) and the European Society of ...
Known for Endometrial Carcinoma | European Society | Gynaecological Oncology | Neoplasms Europe
KOL-Index: 2297 . PURPOSE: Among patients with metastatic breast cancer (mBC), the frequency of germline mutations in cancer susceptibility genes and the clinical relevance of these mutations are unclear. In this study, a prospective cohort of patients with mBC was used to determine mutation rates for breast cancer (BC) predisposition genes, to evaluate the clinical characteristics of patients with ...
Known for Brca1 Genes | Metastatic Breast | Cancer Mbc | Neoplasms Female
KOL-Index: 1129 . Purpose Pertuzumab and T-DM1 are two efficient anti-HER2 treatments for patients with HER2-positive advanced breast cancer. While pertuzumab is usually given in first-line treatment and T-DM1 in second-line treatment, standard therapy options seem to be exhausted up to now after the treatment of patients with these two therapy options. Therefore, it is important to have data that describes ...
Known for Treatment Landscape | Patient Characteristics | Advanced Breast | Therapy Setting
KOL-Index: 819 . PURPOSE: This phase II study determined the efficacy of lacnotuzumab added to gemcitabine plus carboplatin (gem-carbo) in patients with advanced triple-negative breast cancer (TNBC). PATIENTS AND METHODS: Female patients with advanced TNBC, with high levels of tumor-associated macrophages not amenable to curative treatment by surgery or radiotherapy were enrolled. Lacnotuzumab was dosed at ...
Known for Triple Negative | Tumorassociated Macrophages | Cancer Tnbc | Factor 1
KOL-Index: 651 . BACKGROUND: In the phase III OlympiAD trial, olaparib significantly increased progression-free survival (PFS) compared with chemotherapy of physician's choice in patients with germline BRCA-mutated (gBRCAm), human epidermal growth factor 2 (HER2)-negative metastatic breast cancer (mBC). The phase IIIb LUCY trial assessed the clinical effectiveness of olaparib in similar patients, in a ...
Known for Metastatic Breast | Cancer Mbc | Her2 Negative | Received Dose
KOL-Index: 445 . BACKGROUND: Data on institutional structures of sarcoma care in Germany are scarce. The utilization of an interdisciplinary tumor board (IDTB) is an essential part of modern cancer care. We investigated to which extent and when IDTB are used in sarcoma care. We hypothesized that IDTB before treatment initiation were used more often at certified cancer centers and at high-volume centers and ...
Known for 2017 2020 | Study Adds

Key People For Venous Thromboembolism

Top KOLs in the world
#1
John A Heit
venous thromboembolism pulmonary embolism alcohol dependence
#2
Harry Roger Büller
pulmonary embolism venous thrombosis major bleeding
#3
Paolo Prandoni
venous thromboembolism pulmonary embolism vein thrombosis
#4
Samuel Zachary Goldhaber
pulmonary embolism atrial fibrillation major bleeding
#5
Martin Hendrik Prins
venous thromboembolism pulmonary embolism intermittent claudication
#6
Giancarlo Agnelli
venous thromboembolism pulmonary embolism atrial fibrillation

National Center for Tumor Diseases (NCT/UCC), Dresden, Germany | for the ATTAIN Investigators | Department of Gynecology and Obstetrics, Technische Universität Dresden, Dresden, Germany | Helmholtz-Zentrum Dresden–Rossendorf (HZDR), Dresden, Germany